ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2025
Unveiling the role of circulating periostin in patients with idiopathic pulmonary fibrosis: A prognostic meta-analysis.
Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A biomarker-guided framework for corticosteroid treatment stratification in acute exacerbation of idiopathic pulmonary fibrosis.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeriostin measurement has been suggested as a noninvasive biomarker for assessing the likelihood of IPF progression and predicting patient outcomes, but these results aren't entirely consistent. Therefore, we conducted a meta-analysis to study the relation between serum periostin and IPF.
methodsWe conducted a comprehensive search in major electronic biomedical databases of (PubMed, Scopus, Cochrane Library, EMBASE and Web of Science) spanning from inception to September 2024. Meta-analysis of included studies was done, and quantitative data were pooled as standardized mean difference (SMD), odd rations (ORs) and coefficient (r) values , with corresponding 95% confidence intervals (CIs).
resultsEleven articles were included in final meta-analysis. Our results showed that there was no significant difference in periostin levels between IPF patients and healthy controls (SMD: 2.59, 95% CI: -0.59 to 5.77, p= 0.11). Moreover, it was shown that IPF patients with a progressive disease have higher periostin levels compared to those who remain stable (SMD: 0.52, 95% CI: 0.29 to 0.75, p<0.0001). In addition to, higher serum periostin levels were significantly associated with shortened overall survival among IPF patients (RR: 3.70, 95% CI: 1.84 to 7.43, p<0.0001). Finally, there was a significant negative correlation between periostin levels and relative decline in DLCO and VC over the follow-up period (COR: -0.36, 95% CI, -0.58 to -0.10), (COR: -0.49, 95% CI, -0.63 to -0.34) respectively.
conclusionsThis study concludes that periostin may be a valuable biomarker for predicting prognosis in IPF patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.